Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 12/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PRTN3 | P24158 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11325436 | 0.90 | ELANE (0.53) | ELANETDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL11315487 | 0.85 | ELANE (0.61) | ELANETDP1ALDH1A1CYP3A4TSHR | |
| SCHEMBL10932821 | 0.78 | LMNA (0.61) | ELANETDP1ALDH1A1TSHRL3MBTL1 | |
| SCHEMBL4755649 | 0.78 | ELANE (0.79) | ELANEALDH1A1MAPK1 | |
| SCHEMBL10483738 | 0.78 | ELANE (1.00) | ELANEMAPK1 | |
| SCHEMBL7897259 | 0.78 | L3MBTL1 (0.52) | TDP1ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL31336015 | 0.77 | MAOB (0.58) | TDP1ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL4943007 | 0.77 | MAOB (0.58) | TDP1ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL3198417 | 0.77 | TDP1 (0.56) | TDP1ALDH1A1CYP3A4TSHRMAPK1 | |
| SCHEMBL10483679 | 0.76 | ELANE (1.00) | ELANEMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011557-A2 | HETEROARYL INHIBITORS OF RHO KINASE | BORCHARDT ALLEN J (US) | 2008-01-24 | — | — | WO | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | Borchardt, Allen (US) | 2008-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080021217-A1 | HETEROCYCLIC INHIBITORS OF RHO KINASE | ROCK1, ROCK2, RHOA | ELANE 1482/4885TDP1 1214/4885ALDH1A1 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.